CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono […]
CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono […]
CAMBRIDGE, Mass., November 8, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the Stifel 2022 Healthcare Conference on Wednesday November 16,, 2022 at 3:00pm ET in New York, NY. About Casma Therapeutics, Inc. Casma […]
CAMBRIDGE, Mass., May 17, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m. ET in New York, NY. About Casma Therapeutics […]
CAMBRIDGE, Mass., April 7, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to design innovative new medicines, today announced that Casma management will participate in virtual investor meetings on April 14, 2022 at the upcoming 21st Annual Needham Virtual Healthcare Conference being held on Monday, April 11 – Thursday, April 14, 2022. About […]
CAMBRIDGE, Mass., November 10, 2021 – Casma Therapeutics, Inc., a biotechnology company harnessing the power of autophagy to design innovative new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present at the upcoming Stifel Virtual Healthcare Conference on Wednesday, November 17, 2021 at 10 a.m. ET. About Casma Therapeutics Casma Therapeutics is harnessing […]
CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design new medicines, today announced the publication of new research findings in Science Advances co-authored by Casma scientists, along with Oliver Florey, Ph.D., of the Brabraham Institute, and Casma scientific co-founder Andrea Ballabio, M.D., of the Telethon Institute […]
CAMBRIDGE, Mass., September 15, 2021 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer of Casma, will participate in the upcoming virtual UBS Virtual Biotechnology Private Company Symposium being held on September 22-23, 2021. UBS Virtual Biotechnology Private Company […]
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of Sharon Tooze, Ph.D. to its scientific advisory board (SAB). “We are thrilled to welcome Sharon to our SAB at this pivotal stage of Casma’s growth,” stated Leon […]
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET. […]
CAMBRIDGE, Mass. & COPENHAGEN, Denmark- December 1, 2020-Casma Therapeutics, Inc. and Vipergen ApS announced today the signing of a drug discovery agreement. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against a broad range of undisclosed Casma discovery targets. Casma […]